Menu
Recruiting NCT06574191

The Effects of Patient and Visit Characteristics on Health Outcomes in Knee Osteoarthritis

No phase Interventional Knee Osteoarthritis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Topical Diclofenac gel 1%.
Who it may be relevant to
Registry conditions: Knee Osteoarthritis. Basic parameters: from 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this clinical trial is to understand the patient and clinic visit characteristics that affect health outcomes for individuals with knee osteoarthritis (OA) pain using topical diclofenac gel. The main questions it aims to answer are: * What baseline patient characteristics predict response to topical diclofenac? * Does patient physiology during the study visit predict response to topical diclofenac? * Do study visit characteristics predict response to topical diclofenac? Participants will: * attend 2 study visits to complete study questionnaires and have blood drawn * apply topical diclofenac to their knee for 8 weeks * complete biweekly questions about knee pain and diclofenac use between study visits

Detailed description

220 older adults with symptomatic knee OA will attend a single research clinic visit (one of four different types of study visits) with a study clinician. The investigators will video record the visits and measure participant heart rate and skin conductance during the visit. Participants will complete baseline questionnaires immediately prior to the study visit. All participants will receive diclofenac gel (a topical over-the-counter non-steroidal anti-inflammatory drug \[NSAID\]), a guideline recommended treatment for knee OA-related pain at the end of the first study visit. Participants will identify an "index" knee (worst pain, right or left) that they will treat and follow during the study. Between study visit 1 and the 8-week follow-up visit, participants will receive an every other week text message asking them to report on pain and diclofenac use to better understand changes in pain over time. Final questionnaires will be completed at the second study visit at week 8.

Interventions

  • Drug Topical Diclofenac gel 1%
    Topical NSAID

Primary outcome measures

  • Knee Pain [Time frame: 8 weeks]
  • Knee Function [Time frame: 8 weeks]
Secondary outcome measures (6)
  • Global Impressions [Time frame: 30 minutes]
  • Non-verbal Behaviors [Time frame: 30 minutes]
  • Skin conductance index measure [Time frame: 30 minutes]
  • Change in patient skin conductance response [Time frame: 30 minutes]
  • Heart rate variability index measure [Time frame: 30 minutes]
  • Change in patient RMSSD (root mean square of successive differences) [Time frame: 30 minutes]

Eligibility criteria

Inclusion criteria

  • English-speaking
  • 50 years of age or older
  • Radiographically confirmed knee OA of K/L grade 2 or higher within the past 2 years
  • Knee pain at least 15 days/month.
  • Average worst daily pain 3/10 or higher over a two-week period.

Exclusion criteria

  • Medical contraindication to taking NSAIDs such as: history of coronary artery bypass graft, myocardial infarction, coronary artery stent placement, or stroke within the past 6 months; systolic heart failure with ejection fraction <45%; chronic kidney disease stage ≥4; severe gastrointestinal bleed or stomach ulcer within the past 6 months; current pregnancy; cirrhosis; currently taking blood thinners (aspirin 81 mg daily is okay); allergy to NSAIDs or aspirin; or any other medical contraindication to using topical NSAIDs.
  • Inflammatory arthritis
  • Partial or total knee replacement of the index knee
  • Recent therapeutic injection of the index knee (less than 12 weeks)
  • Planned knee/lower limb surgery during the two-month study period
  • Active cancer treatment not in remission or life expectancy less than 6 months
  • Inability to provide informed consent (e.g. dementia)
  • Current use of topical or oral NSAIDs more than 3 days per week.
  • Inability to receive text messages or emails to complete questionnaires between study visits.
  • Unable to follow the study protocol.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of California Davis Health — Sacramento

Identifiers

NCT: NCT06574191 · 2054088 · R01AG078283

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗